Neumentum, Inc. Nominated for Two Citeline Awards

Neumentum, Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that it has been nominated for two Informa Pharma Intelligence Citeline Awards including the Most Successful Early Stage Research and Clinical Trial Result of the Year categories.

Continuous Ketorolac Infusion Formulation Predicted to Provide Rapid-Onset Pain Relief

There is strong evidence that a continuous infusion formulation of ketorolac (NTM-001, Neumentum) achieves a fast onset of effective analgesia that is maintained at a stable level over 24 hours, based on initial results of a phase 1 trial and a PubMed literature review of infusion trials in a variety of major surgical procedures.

All rights reserved, including copyright 2020, Neumentum, Inc